Effective cholesterol management is an important factor in reducing cardiovascular (CV) risks in patients with diabetes, coronary heart disease and following myocardial infarction (MI)2-3. When reducing CV risk, drug treatments like statins are only part of the solution. With decades of expertise in cardio-metabolic health, Abbott offers a range of supporting treatments for patients with dyslipidemia, to help people lead healthier lives.




  1. Lim SS et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
  2. ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus N Engl J Med. 2010;362: 1563–1574.
  3. GISSI-P Investigators 1999] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet. 1999;354:447–455.
  4. World Health Day 2013. A global view on Hypertension, World Health Organization, 2013.
    Available at:
  5. Lipanthyl Summary of Product Characteristics. Local SMPC to be referenced while respecting the local indications
  6. ACCORD Study Group; ACCORD Eye Study Group et al. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes N Engl J Med. 2010;363:233–244.